Centiva Capital’s MaxCyte MXCT Stock Holding History

Centiva Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31,518	Closed	-$86K	–	1891
2025 Q1	$86K	Buy	31,518 +6,525	+26%	+$25.7K	﹤0.01%	1410
2024 Q4	$104K	Buy	+24,993	New	+$94.5K	﹤0.01%	1490
2024 Q2	–	Sell	-36,591	Closed	-$153K	–	2353
2024 Q1	$153K	Buy	+36,591	New	+$172K	﹤0.01%	1538
2022 Q1	–	Sell	-14,910	Closed	-$152K	–	1739
2021 Q4	$152K	Buy	+14,910	New	+$160K	﹤0.01%	1026

Other funds holding MXCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centiva Capital's MXCT Position: Q2 2025 in Review

Centiva Capital sold out of MaxCyte (MXCT) in Q2 2025, closing a stake of 31,518 shares — an estimated $86K sold.

Centiva Capital first reported a position in MXCT in Q4 2021 and held it in 4 quarters. The position peaked at $153K in Q1 2024. 120 funds tracked by Wall St. Rank hold MXCT as of Q2 2025.

Centiva Capital reported no remaining MaxCyte position as of Q2 2025 after selling out during the quarter.
Centiva Capital sold 31,518 MaxCyte shares in Q2 2025, an estimated $86K.
Centiva Capital first reported a position in MaxCyte in Q4 2021 and held it in 4 quarters.
Centiva Capital's MaxCyte position peaked at $153K in Q1 2024.
120 funds tracked by Wall St. Rank held MaxCyte as of Q2 2025.

Based on Centiva Capital's 13F filing for Q2 2025, filed 13 Aug 2025.